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Abstract
Health Issues: Differences exist in the prevalence and physical health impacts of problem
substance use among men and women. These differences are also found in the mental health and
trauma events related to substance use, barriers to treatment and harm-reduction services and the
impact of substance use on pregnancy and parenting. Data from the 2000–2001 Canadian
Community Health Survey and Canada's Alcohol and Other Drugs Survey (1994) were used to
explore this issue further.
Key Findings: While women use alcohol and illicit drugs at lower rates than men, the health
impact of their use is significant, and in some cases greater than for men. Women are more likely
to use prescribed psychoactive drugs (e.g. pain relievers, sleeping pills, tranquillizers) and most of
these drugs have addictive potential and long-term negative consequences on health. Research
collected from treatment centres in Canada show high rates of victimization experienced by
women, which have implications for both their substance use treatment and improvement in
mental health.
Data Gaps and Recommendations: Significant gaps exist in our knowledge on the level, type,
and impact of substance use and the adequacy of programming for Canadian women. Information
that might be used to guide prevention initiatives, such as the amount of alcohol that might safely
be used in pregnancy and the incidence of fetal alcohol syndrome, related birth defects and
developmental disabilities are unknown. Improved surveillance, sensitive and comprehensive
screening for substance use problems, accessible treatment and harm reduction programming, and
coordination with the mental health and violence fields are recommended.
Background
It is particularly challenging to provide policy-relevant
information on women in the area of substance use and
misuse, as the topic covers such broad territory. Problem
substance use has been found to arise from a complex
interplay of biological, genetic, psychological, social, cul-
tural, relational, environmental and spiritual factors.
Because of the interplay of these factors, it remains a chal-
lenge for policy makers and program planners to develop
and implement the very broad, collaborative, systemic
responses required and to do so in a manner that links
prevention, enforcement, harm reduction and treatment
strategies. In spite of the overall challenges, advances in
gender-specific policy and programming are especially
worthy of consideration and could be of tremendous ben-
efit to the health of women and their families.
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This chapter presents findings from both surveillance
sources and select research reports. As there has not been
recent or adequate surveillance specific to substance use
by Canadians, cross-sectional data from the Canadian
Community Health Survey (CCHS) Cycle 1.1 (2000) are
highlighted. While trends in women's substance use and
substance use problems could not be provided, an over-
view of key research findings is offered that supports a
comprehensive understanding of the topic from a gender
perspective and places the findings of the CCHS in the
appropriate context. Readers are encouraged to consult
existing research reports mentioned throughout the chap-
ter to further their understanding of this complex topic.
Physical Health Impact of Problem Substance Use
Health Canada's Straight Facts about Drugs and Drug
Abuse [1] outlines the health consequences of high doses
of all classes of psychoactive substances, including stimu-
lants, hallucinogens, cannabis and central nervous system
depressants (opioid analgesics, alcohol, inhalants/sol-
vents, benzodiazepines, barbiturates).
For some drug classifications, evidence of sex differences
in the physical health impact of substance use is available.
[2] To take alcohol as an example, women metabolize
alcohol and other psychoactive substances more slowly
than men, allowing harmful metabolites to remain longer
in the body. Women are more likely than men to develop
cirrhosis of the liver after consuming lower levels of alco-
hol over a shorter period of time. [3,4] These findings also
apply to brain shrinkage and impairment, [5-7] breast
cancer, [8-12] gastric ulcers [13] and alcoholic hepatitis.
[14]
Although there is not adequate research on sex differences
in the impact of illicit drugs, gender differences are begin-
ning to be documented. [15] Injecting drug use (IDU) is a
key risk factor among women for the transmission of
blood-borne diseases such as HIV/AIDS and hepatitis C.
[16] Also linked to illicit drug use are high-risk sexual
behaviours (e.g. sex trade work), which, in turn, are asso-
ciated with a range of negative health impacts. [17]
Mental Health, Trauma and Substance Use
Research has shown that as many as two thirds of women
with substance misuse problems may have a concurrent
mental health problem, such as depression, post-trau-
matic stress disorder, panic disorder and/or an eating dis-
order. [18] Research also shows that a large proportion of
women with substance use problems are victims of
domestic violence, incest, rape, sexual assault and child
physical abuse. [19-22] Victimization has been linked to a
variety of negative outcomes, including post-traumatic
stress disorder, depression, anxiety, suicidal behaviour
and low self-esteem among women in the general popu-
lation. [23,24] Compared with non-abused clients,
women in treatment for problem substance use who have
been victimized are more likely to suffer from depression
and suicidal ideation, have lower self-esteem, negative
psychological adjustment and more post-traumatic stress
symptoms. [25-30]
Pregnancy, Mothering and Substance Use
Substance use by pregnant women and mothers has
received a great deal of attention, and there is a volumi-
nous literature documenting the adverse effects of alco-
hol, tobacco and other drugs on the fetus. Alcohol use
during pregnancy, particularly in combination with poor
nutrition, poor general health, experience of trauma and
mental health problems, and lack of prenatal care, has
been found to have the most harmful effects. [31,32]
Maternal use of licit and illicit drugs can also result in
problems that have short- or long-term consequences for
those prenatally exposed. However, study of the impact of
these drug categories is hampered by methodological
flaws that fail to take into account the use of more than
one drug. [33] Rather than the provision of effective out-
reach, engagement and treatment, the responses in some
countries and to some extent in Canada towards women
who use illicit substances during pregnancy have been
blame, attempts to force women into treatment, and even
criminal sanctions. [34-37]
The Health Canada document entitled Best Practices: Fetal
Alcohol Syndrome/Fetal Alcohol Effects and the Effects of
Other Substance Use during Pregnancy [32] provides a
comprehensive view of the issues and of promising fetal
alcohol syndrome (FAS) prevention practices grounded in
both the literature and the expertise of Canadians working
in the field. Programs such as the Breaking the Cycle Pro-
gram in Toronto and the Sheway Program in Vancouver
are examples of effective programs being developed in
Canada to serve women at high risk of having a child
affected by FAS.
Stigma and Barriers to Treatment for Women
In the forefront of psychosocial influences on women's
misuse of alcohol and other drugs is the stigma arising
from societal attitudes towards women's substance use.
[38] This stigma causes women to feel considerable guilt
and shame as their substance use/misuse continues and
creates barriers to their accessing help. [39-43] The stigma
associated with women's substance use affects service pro-
viders as well. Women often encounter mis-information,
denial, inaction and even punitive attitudes towards their
substance use by professionals in a position to intervene,
and thus they may not be identified as needing help.
[37,44-46]BMC Women's Health 2004, 4:S8 http://www.biomedcentral.com/1472-6874/4/S1/S8
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Stigma intersects with structural and other barriers that
arise from experience of victimization and mental health
problems, fear of having one's children apprehended,
minority status, income and rural location, to name but a
few. Health Canada's report Best Practices: Treatment and
Rehabilitation of Women [40] has been developed as a
key resource for health care providers in helping to reduce
barriers to treatment access for diverse groups of sub-
stance-using women.
The barriers to accessing supportive treatment services are
even greater for pregnant and parenting women. Pro-
grams that accept both mothers and children are very
scarce. Finding affordable and safe care for their children
as well as residential care is often an overwhelming obsta-
cle for mothers needing treatment. [47] Although outpa-
tient counselling and other supports for pregnant and
parenting women have been made available, appalling
barriers remain for mothers in need of residential treat-
ment for problem substance use in Canada.
Gender and Harm Reduction Approaches
Harm reduction is a newer policy approach to substance
misuse, which arose initially as a response to the spread of
AIDS among injection drug users. [48] The primary goal
of harm reduction policy and practice is a reduction in the
negative consequences associated with use rather than
complete cessation of substance use. Key harm reduction
programs and policies in Canada relating to illicit drugs
include methadone maintenance; needle/syringe
exchange; supervised injection sites; increased attention
to the decriminalization of use of small quantities of can-
nabis; and education, information and diversion pro-
grams. Such initiatives can be beneficial to women who
are drug users and/or who have partners who are drug
users in helping prevent HIV transmission, improve their
access to drug treatment and health care services, prevent
birth defects and disabilities in their children, make incar-
ceration experiences safer, and stabilize their health over-
all. Particularly promising is harm reduction
programming offered to high-risk, marginalized pregnant
women and their support networks, an approach that has
been shown to prevent FAS and other alcohol- and drug-
related disabilities, support retention of custody, and
increase the health and social stability of both mothers
and children. [47]
The Current Study
We explored the use of alcohol, licit and illicit substances
by Canadian women and subgroups of women (including
girls, elderly women, Aboriginal women and pregnant
women). Additionally, the health consequences of sub-
stance use, and the coexistence of mental health, trauma
and substance use issues, were explored.
Methods
Data
Cross-sectional data from the Canadian Community
Health Survey (CCHS) Cycle 1.1 (2000–2001) [49] are
presented below. The data are weighted to represent the
Canadian population. Age-adjusted data are presented
where appropriate. The sample comprised 125,574 indi-
viduals, aged 12 years and older, from across all provinces
and territories. Data from other sources (including select
research reports, such as the Canadian Profile on Alcohol,
Tobacco and Other Drugs [50]) are similarly provided to
highlight what is known about the use of alcohol, licit and
illicit drugs by women, and the effects of this use. Where
pertinent, comparisons between females and males are
made.
It is important to note that comparability issues arise
when different surveys, data sources and research reports
are compared. Key issues of concern are related to design
(e.g. the jurisdictions included in the survey) and method-
ology (e.g. the form of the survey – telephone or face-to-
face interviews). For a full understanding of the compara-
bility of the research studies reported on here, the reader
is encouraged to consult the original source. Likewise, it is
important to point out some of the key limitations of gen-
eral population surveys. These include the difficulty in
obtaining information from and about hard-to-reach
populations (heavy substance users living on the street or
in an institution), under-reporting because the behaviour
is socially sanctioned, recall difficulties, and/or under-
reporting of psychoactive medication use among older
adults due to their lack of awareness of the reasons for tak-
ing multiple medications. Nonetheless, survey instru-
ments are able to provide information regarding the
lower-bound estimates of substance use measures impor-
tant to public health monitoring. [50]
Measures
Alcohol Use
Data from the Alcohol (and Breast-feeding) modules of
the CCHS were extracted in order to determine lifetime
use of alcohol, alcohol use and frequency of use in the
previous 12 months, heavy drinking (defined here as five
or more drinks on at least one occasion at least once per
month), and alcohol use and frequency of use in last preg-
nancy. Differences by sex, age and Aboriginal status were
explored. Data examined by Single and colleagues from
1994 to 1995 and 1995 to 1996 from the Canadian Insti-
tute for Health Information (CIHI) on hospital separa-
tions attributed to alcohol use are strongly endorsed
within the field and are also presented. [51]
Licit Drug Use
Data from the Drug Use module of the CCHS were
extracted in order to determine the use of the followingBMC Women's Health 2004, 4:S8 http://www.biomedcentral.com/1472-6874/4/S1/S8
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licit substances: pain relievers, tranquilizers, diet pills,
antidepressants, opioid analgesics (such as codeine,
Demerol or morphine), and sleeping pills. Only partici-
pants from Ontario (all health regions) were administered
the Drug Use module of the CCHS. As a result, findings
may not be generalizable to other provinces and territo-
ries. Differences by sex, age and Aboriginal status were
explored. The literature on the health consequences of
long-term licit drug use is summarized.
Illicit Drug Use
Information about illicit drug use was not collected
through the CCHS Cycle 1.1, therefore data from the 1994
Canada's Alcohol and Other Drugs Survey (CAODS),[52]
the 1998 Canadian Campus Survey [53] and hospital sep-
arations attributed to illicit drug use [51] are presented.
Mental Health Issues, Trauma and Substance Use
Data from the Depression, Contacts with Mental Health
Professionals, and Suicidal Thoughts and Attempts mod-
ules of the CCHS Cycle 1.1 were extracted in order to
explore the relation between mental health issues and
substance use in women. Seventy of the 136 health
regions in Canada (all in the provinces of Nova Scotia,
New Brunswick, Quebec, Manitoba, Alberta, and a few in
Ontario) administered the Suicidal Thoughts and
Attempts questionnaire. All but two health regions
administered the Depression questionnaire. Data con-
cerning rates of trauma among substance-using women in
treatment centres in Canada are presented.
Results
Alcohol Use
Prevalence
According to the 2000–2001 CCHS, [49] 73.1% of Cana-
dian women aged 12 years and older had used alcohol at
least once in the previous year and 13.3% reported using
alcohol during their lifetime but not in the previous year
(see Figure 1). Alcohol use was more prevalent among
males than females. The majority of females who reported
having had a drink in the previous year tended to drink
infrequently (see Figure 2).
The rate of alcohol use in the previous 12 months among
adolescent girls aged 15 to 19 years was 71.1% and among
Canadian women, on average, was 75.5%. It appears that
more Aboriginal than non-Aboriginal women reported
ever drinking alcohol and drinking alcohol in the previ-
ous 12 months. Roughly 11% of the women reporting
alcohol use in the previous 12 months met the criterion
for any occasion heavy drinking. Twice as many Aborigi-
nal women as non-Aboriginal women met this criterion.
Alcohol Use in Pregnancy
Fourteen percent of all women who indicated that they
consumed alcohol in their lifetime also reported that they
had consumed alcohol during their last pregnancy. The
vast majority of women reporting alcohol use during a
pregnancy reported drinking infrequently: 75.4% drank
less than once per month; 9.7% drank once per month;
6.5% drank two to three times per month; 5.3% drank
once per week; and 1.3% drank every day.
Morbidity
Single and colleagues [51] examined 1994–1995 and
1995–1996 data from CIHI and 1991–1992 data from the
then Laboratory Centre for Disease Control, Health Can-
ada, on hospital separations attributable (fully and par-
tially) to alcohol (e.g. alcohol toxicity, alcoholic liver
cirrhosis) and estimated that 29,181 women (51,765
men) were hospitalized in 1995–1996 because of alcohol.
The greatest number of hospitalizations among women
was for accidental falls (7,689), followed by motor vehicle
accidents (3,433), alcohol dependence syndrome (3,247)
and suicide/self-injury (2,473). Hospital separations per
100,000 have remained fairly stable among women (from
206 in 1991–1992 to 193 in 1995–1996) and have
declined among men (from 401 in 1991–1992 to 349 in
1995–1996).
Mortality
According to Single and colleagues' analysis of 1995 CIHI
data, the estimated number of deaths attributed (fully and
partially) to alcohol consumption among hospitalized
women was 1,823 or 12.4 per 100,0000 population
(among men it was 4,681 or 32.3 per 100,000 popula-
tion). The greatest number of deaths among women was
attributed to motor vehicle accidents (357), alcoholic
liver cirrhosis (257), accidental falls (202), breast cancer
(192), alcohol dependence syndrome (135) and suicide/
self-inflicted injury (134). The potential years of life lost
in 1995 were estimated at 48,392 for women or 327.9 per
100,000 population (123,734 for men or 853.7 per
100,000 population).
Licit Drug Use
Note: The licit drug use identified in the CCHS survey
should not be seen as indicating misuse or problemuse.
Prevalence
According to the 2000–2001 CCHS, the proportion of
females aged 12 or older reporting use in the previous year
of selected prescription and non-prescription drugs was
23.7% for pain relievers, 2.1% for opioid analgesics, 1.7%
for sleeping pills, 1.1% for tranquilizers, 2.1% for antide-
pressants and 0.4% for diet pills. Females consistently
reported higher rates of use than males in all categoriesBMC Women's Health 2004, 4:S8 http://www.biomedcentral.com/1472-6874/4/S1/S8
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(see Figure 1). Non-Aboriginal women were more likely
than Aboriginal women to report the use of pain relievers
and sleeping pills.
Morbidity
Women were twice as likely as men to have benzodi-
azepines prescribed to them for "non-clinical" symptoms,
[54] such as stress from work or home life, grief, acute or
chronic illness, physical pain or adjustment to a major life
change, [55-57] and to have them prescribed for longer
periods. [58] It is becoming clear that women are over-
prescribed benzodiazepines to cope with difficult life cir-
cumstances rather than to relieve severe clinical symp-
toms. Long-term benzodiazepine use is associated with
several negative health consequences. The sedative/hyp-
notic effects of these drugs place elderly individuals at
Prevalence of Alcohol Use, Licit Drug Use and Illicit Drug Use in Canada by Sex and Aboriginal Status Figure 1
Prevalence of Alcohol Use, Licit Drug Use and Illicit Drug Use in Canada by Sex and Aboriginal StatusBMC Women's Health 2004, 4:S8 http://www.biomedcentral.com/1472-6874/4/S1/S8
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increased risk of psychomotor, cognitive and memory
impairment; [59] emotional clouding; violent behaviour;
depression; [60] and hip and femur fractures. [61,62]
Illicit Drug Use
Prevalence
Overall, self-reported illicit drug use by females in Canada
is low (see Figure 1). Data from the 1994 CAODS [52]
show that the proportion of females aged 15 and older
reporting use of selected illicit drugs in the previous year
was 5.1% for cannabis, 0.7% for LSD, speed or heroin,
and 0.5% for cocaine. When these proportions are com-
pared with data on lifetime use of illicit drugs from the
same survey, the rates of use in each of the three categories
decrease slightly: 18.7% for cannabis, 3.6% for LSD, speed
or heroin, and 2.7% for cocaine. More recent data (1998
Canadian Campus Survey [53]) reveal comparatively high
rates of illicit drug use among university students
(although these figures do not represent the use among
Canadians in general): 8.9% of female students reported
use of illicit drugs in the previous 12 months (not includ-
ing cannabis) and 28.0% reported cannabis use. Illicit
drug use by males was higher than by females inall
categories.
Injecting drug use (IDU) provides a good illustration of
the need for a gender-based analysis of illicit drug use.
Surveillance data from the Centre for Infectious Disease
Prevention and Control, Health Canada, [16] reveal that
up to December 31, 2000, IDU was identified as the risk
factor in 1,123 reported positive HIV cases in women and
in 2,570 cases in men. Figure 3 shows that, among both
females and males, there has been a decrease over time in
the number of positive tests attributable to IDU. However,
IDU is a greater risk for females, accounting for an average
of 45.7% of all female HIV cases and only 25.6% of all
male cases from 1995 to 2000. Over this six-year period
there was a substantial decrease of IDU as a risk factor for
HIV among females (from 53.6% cases in 1995 to 38.5%
in 2000), whereas among men the rate remained
relatively stable (from 23.6% cases in 1995 to 22.4% in
2000).
There are extremely limited Canadian data on solvent use.
Information from the CAODS shows that 0.3% of females
aged 15 and older reported use of a solvent(s) throughout
their lifetime. The Ontario Student Drug Use Survey [63]
reported that between 1977 and 2001, the average preva-
lence of glue sniffing with the intention of getting high
among females during the previous 12 months was 2.1%;
the percentage was highest in 1999 (3.7%) and lowest in
1991 (1.1%).
Morbidity
From their analysis of hospital separations attributed
(fully and partially) to illicit drugs, Single and colleagues
estimated that 2,405 women (4,542 men) were hospital-
ized in 1995–1996 because of illicit drugs. [5] The hospi-
talizations for women were a result of drug psychoses
(768), followed by cocaine dependence or abuse (375),
psychotropic poisoning (323), and opioid dependence/
abuse (314). The number of hospital separations per
100,000 population has remained fairly stable between
1991–1992 and 1995–1996 for women and men.
Mortality
According to Single and colleagues' analysis of 1995 CIHI
data, the number of deaths attributable to illicit drugs was
estimated at 108 for hospitalized women or 0.7 per
100,000 population (695 for men or 4.8 per 100,000
population). The greatest number of deaths resulted from
opiate poisoning (42), poisoning (intent undetermined)
(23), AIDS (18), suicide/self-inflicted injury (15) and
cocaine poisoning (11). The potential years of life lost in
1995 were estimated at 4,959 for women or 33.6 per
100,000 population (28,710 for men or 198.1 per
100,000 population).
Mental Health, Trauma and Substance Use
Mental Health and Substance Use
Of the women meeting the criterion for heavy drinking,
25.7% reported feeling sad, blue or depressed in the pre-
vious two weeks. Depression can be a precursor or ante-
cedent of problem alcohol use, or both. Roughly 15% of
heavy drinking women also reported visiting a mental
health professional in the previous 12 months. Further,
18.6% of them reported that they had previously seriously
considered committing suicide. Of the women who had
Patterns of Alcohol Consumption among Women who  Reported Having had a Drink in the Previous 12 Months:  Canadian Community Health Survey [49] Figure 2
Patterns of Alcohol Consumption among Women who 
Reported Having had a Drink in the Previous 12 Months: 
Canadian Community Health Survey [49]BMC Women's Health 2004, 4:S8 http://www.biomedcentral.com/1472-6874/4/S1/S8
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considered suicide in the previous 12 months, 37.3% had
previously attempted to take their own life.
Trauma and Substance Use
Research shows high rates of victimization among sub-
stance-abusing women. [15] Data collected from sub-
stance use treatment centres in Canada corroborate these
estimates. In a sample of substance-abusing women from
nine treatment centres across Ontario, Cormier [64]
found that 85.7% of the 98 women in her sample had
been victimized. They were most likely to have reported
being a victim of adult physical abuse (56.1%), childhood
sexual abuse (56.3%), childhood physical abuse (56.1%)
and adult sexual abuse (45.4%). A treatment facility for
substance-abusing women in Vancouver (Aurora Centre)
reported that 65% of its female clients had been physically
assaulted as adults, and 38% had been sexually assaulted;
47% reported physical violence in childhood, and 53%
reported sexual abuse at that time. [47]
Discussion
Data Limitations
The past quarter-century has been characterized by incon-
sistent survey data collection on substance use and abuse
at the national, provincial/territorial and municipal lev-
els. Further, there has been limited recognition in the
research that social factors specific to sex and gender (e.g.
employment, cultural displacement, abuse) have a signif-
icant role in substance use problems. An overarching lim-
itation of most surveys and research studies is the marked
discrepancy in definitions of substance use, dependence,
or problematic use.
In comparison with current information on alcohol use
and abuse in Canada, there is extremely limited
knowledge of illicit and licit drug use and, in particular,
the associated morbidity and mortality. Gender-specific
research on prescription and non-prescription drug use is
required, since females consistently report higher rates of
use than males, thus increasing the probability of prob-
lematic use. Health Canada and pharmaceutical company
data (e.g. PURDUE Pharma) are alternative sources of
information on the dispensing practices of physicians. In
addition, there has been collection of drug plan utiliza-
tion data at the provincial level (e.g. New Brunswick, Sas-
katchewan) that could be replicated. Further, while the
first cycle of the CCHS Cycle 1.1 did not include questions
about illicit drug use, the most recent cycle of the survey
(CCHS Cycle 1.2) will be an appropriate source from
which to collect this information.
There are also knowledge gaps concerning substance use
and misuse, and concerning competent programming
that addresses the needs of poor women, rural women,
homeless women, women with disabilities, lesbians, eld-
erly women, adolescent girls and women from different
ethnic backgrounds, all of whom are often at increased
risk for general health problems. The limited data availa-
ble suggest that these subpopulations of women may be
at greater risk of substance use problems than the general
population. [65-73]
Several suggestions to address the current data limitations
follow. Each of these requires the collection of sex- and
gender-specific data.
Number of Positive HIV Test Reports Attributable to Injecting Drug Use (IDU) among Adult Females and Males 15 Years of  Age and Older, by Year of Test [16] Figure 3
Number of Positive HIV Test Reports Attributable to Injecting Drug Use (IDU) among Adult Females and Males 15 Years of 
Age and Older, by Year of Test [16]BMC Women's Health 2004, 4:S8 http://www.biomedcentral.com/1472-6874/4/S1/S8
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Recommendations
Incidence and Prevalence Data
1. Surveillance in the form of a national incidence/preva-
lence survey should be carried out on a regular basis (e.g.
every three years).
2. Canada should provide more support for its substance
use monitoring systems, such as the Canadian Commu-
nity Epidemiology Network on Drug Use, [74] so that
data will be readily available and attempts to collate data
in reports such as this one will not be such a daunting
task. Integral to such a system must be the reporting of
data by sex, attention to social and other determinants of
women's substance use, and the exploration of substance
use problems in relation to gender.
Treatment Data
3. There is a need to develop a mechanism for capturing
evaluation data on substance use interventions (including
women-specific interventions at various levels of care).
4. There is also a need to examine the availability of data
collected from special populations (e.g. National Youth
Solvent Abuse Program, First Nations and Inuit Health
Branch).
Mortality and Morbidity Data
5. Greater and affordable access to national systems for
collecting and reporting information on hospitalizations
is necessary (i.e. CIHI); all aspects of the standardization
in data collection must be addressed (e.g. ICD-9/10
codes); and hepatitis C in addition to HIV/AIDS should
be included.
Other Data Fundamental to Women-Centred Policy and 
Programming
6. Central to action on women's substance use is address-
ing the misinformation and prejudice directed at women
with this common health-related problem. This is essen-
tial in order to help reduce the guilt and shame that pre-
vent women from identifying both that they use
substances and that they need help. This approach should
underlie all the following recommendations.
Reducing Barriers to Identifying and Preventing FAS
7. There is a need to identify viable and sensitive methods
for implementing screening for substance use by women
on the part of a wide range of professionals in a position
to make referrals to treatment and other resources when
necessary. It is particularly important for this screening to
be in place to reach women of child-bearing years and
pregnant women, so that FAS and other alcohol- and
drug-related developmental disabilities are prevented.
Some surveys on alcohol and drug screening practices of
physicians have been done, and such surveys can assist in
promoting tailored training and action in this important
area.
Understanding and Responding to Diverse Needs
8. Knowledge gaps need to be addressed concerning the
level, type and impact of substance use and the adequacy
of programs that should be reaching vulnerable sub-
groups of women (e.g. Aboriginal women, poor women,
homeless women, lesbians, women living in rural areas).
For the most part, these would require smaller-scale, local
studies.
Understanding the Impact of Illicit Drug Use on Women 
and Harm Reduction Approaches
9. There is a critical need for data on sex and gender differ-
ences in the experience of illicit drug use and the potential
need for, and impact of, harm-reduction-oriented policy
and programming.
Improving Treatment Access, Especially for Mothers
10. Data on the impact of barriers to treatment are
needed. Treatment programming that addresses sex and
gender differences in the experience of addictions needs to
be made more accessible to women in Canada. Program-
ming that is accessible and relevant to women who are
mothers is of particular priority.
Blending Treatment/Support in Substance Use, Mental 
Health and Trauma Concerns
11. It is recommended that linkages be enhanced (and in
some cases program integration be considered) between
mental health treatment, substance misuse treatment and
programming for women who have experienced trauma/
relationship violence, in order to address the strong inter-
connections among these three serious health problems
for women.
Notes
The authors wish to acknowledge the contributions of
Bette Reimer, Canadian Centre on Substance Abuse, who
conducted literature searches for this chapter, and Karen
Devries, who assisted with the organization of the refer-
ence section for this chapter.
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